nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP3A4—Temozolomide—melanoma	0.163	0.385	CbGbCtD
Tolterodine—CYP2D6—Vemurafenib—melanoma	0.14	0.332	CbGbCtD
Tolterodine—CYP3A4—Vemurafenib—melanoma	0.0891	0.211	CbGbCtD
Tolterodine—CYP3A4—Docetaxel—melanoma	0.0306	0.0724	CbGbCtD
Tolterodine—Influenza-like symptoms—Temozolomide—melanoma	0.00652	0.0261	CcSEcCtD
Tolterodine—Dry skin—Vemurafenib—melanoma	0.00606	0.0243	CcSEcCtD
Tolterodine—Memory impairment—Temozolomide—melanoma	0.00593	0.0237	CcSEcCtD
Tolterodine—Influenza like illness—Temozolomide—melanoma	0.00452	0.0181	CcSEcCtD
Tolterodine—Oedema peripheral—Vemurafenib—melanoma	0.00451	0.018	CcSEcCtD
Tolterodine—Disorientation—Bleomycin—melanoma	0.00448	0.0179	CcSEcCtD
Tolterodine—Dry eye—Temozolomide—melanoma	0.0043	0.0172	CcSEcCtD
Tolterodine—Abnormal vision—Carmustine—melanoma	0.0042	0.0168	CcSEcCtD
Tolterodine—Abnormal vision—Temozolomide—melanoma	0.00406	0.0163	CcSEcCtD
Tolterodine—Arthralgia—Vemurafenib—melanoma	0.00339	0.0136	CcSEcCtD
Tolterodine—Anaphylactic shock—Vemurafenib—melanoma	0.00325	0.013	CcSEcCtD
Tolterodine—Infection—Vemurafenib—melanoma	0.00323	0.0129	CcSEcCtD
Tolterodine—Dry skin—Temozolomide—melanoma	0.0031	0.0124	CcSEcCtD
Tolterodine—Influenza like illness—Docetaxel—melanoma	0.00301	0.012	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00296	0.0119	CcSEcCtD
Tolterodine—Bronchitis—Temozolomide—melanoma	0.00281	0.0112	CcSEcCtD
Tolterodine—Fatigue—Vemurafenib—melanoma	0.0028	0.0112	CcSEcCtD
Tolterodine—Constipation—Vemurafenib—melanoma	0.00278	0.0111	CcSEcCtD
Tolterodine—Dysuria—Temozolomide—melanoma	0.00273	0.0109	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Temozolomide—melanoma	0.00272	0.0109	CcSEcCtD
Tolterodine—Weight increased—Temozolomide—melanoma	0.00266	0.0106	CcSEcCtD
Tolterodine—Urinary tract infection—Carmustine—melanoma	0.00262	0.0105	CcSEcCtD
Tolterodine—Flushing—Bleomycin—melanoma	0.00257	0.0103	CcSEcCtD
Tolterodine—Urinary tract infection—Temozolomide—melanoma	0.00253	0.0101	CcSEcCtD
Tolterodine—Sinusitis—Temozolomide—melanoma	0.00244	0.00978	CcSEcCtD
Tolterodine—Hallucination—Carmustine—melanoma	0.00241	0.00963	CcSEcCtD
Tolterodine—Flushing—Dactinomycin—melanoma	0.0024	0.0096	CcSEcCtD
Tolterodine—Hypersensitivity—Vemurafenib—melanoma	0.0024	0.00958	CcSEcCtD
Tolterodine—Oedema peripheral—Carmustine—melanoma	0.00238	0.00954	CcSEcCtD
Tolterodine—Asthenia—Vemurafenib—melanoma	0.00233	0.00933	CcSEcCtD
Tolterodine—Visual impairment—Carmustine—melanoma	0.00233	0.00933	CcSEcCtD
Tolterodine—Hallucination—Temozolomide—melanoma	0.00233	0.00931	CcSEcCtD
Tolterodine—Oedema peripheral—Temozolomide—melanoma	0.0023	0.00922	CcSEcCtD
Tolterodine—Visual impairment—Temozolomide—melanoma	0.00225	0.00902	CcSEcCtD
Tolterodine—Flushing—Carmustine—melanoma	0.00225	0.00899	CcSEcCtD
Tolterodine—Diarrhoea—Vemurafenib—melanoma	0.00222	0.0089	CcSEcCtD
Tolterodine—Flushing—Temozolomide—melanoma	0.00217	0.00868	CcSEcCtD
Tolterodine—Dizziness—Vemurafenib—melanoma	0.00215	0.0086	CcSEcCtD
Tolterodine—Dry skin—Docetaxel—melanoma	0.00206	0.00824	CcSEcCtD
Tolterodine—Chest pain—Bleomycin—melanoma	0.00206	0.00822	CcSEcCtD
Tolterodine—Headache—Vemurafenib—melanoma	0.00204	0.00815	CcSEcCtD
Tolterodine—Confusional state—Bleomycin—melanoma	0.00199	0.00795	CcSEcCtD
Tolterodine—Anaphylactic shock—Bleomycin—melanoma	0.00197	0.00788	CcSEcCtD
Tolterodine—Oedema—Bleomycin—melanoma	0.00197	0.00788	CcSEcCtD
Tolterodine—Infection—Bleomycin—melanoma	0.00196	0.00783	CcSEcCtD
Tolterodine—Angioedema—Temozolomide—melanoma	0.00186	0.00744	CcSEcCtD
Tolterodine—Oedema—Dactinomycin—melanoma	0.00184	0.00735	CcSEcCtD
Tolterodine—Vertigo—Temozolomide—melanoma	0.00183	0.00732	CcSEcCtD
Tolterodine—Infection—Dactinomycin—melanoma	0.00183	0.0073	CcSEcCtD
Tolterodine—Palpitations—Temozolomide—melanoma	0.0018	0.0072	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Bleomycin—melanoma	0.00179	0.00718	CcSEcCtD
Tolterodine—Chest pain—Carmustine—melanoma	0.00179	0.00718	CcSEcCtD
Tolterodine—Anxiety—Carmustine—melanoma	0.00179	0.00715	CcSEcCtD
Tolterodine—Weight increased—Docetaxel—melanoma	0.00177	0.00708	CcSEcCtD
Tolterodine—Confusional state—Carmustine—melanoma	0.00173	0.00694	CcSEcCtD
Tolterodine—Arthralgia—Temozolomide—melanoma	0.00173	0.00693	CcSEcCtD
Tolterodine—Anxiety—Temozolomide—melanoma	0.00173	0.00691	CcSEcCtD
Tolterodine—Oedema—Carmustine—melanoma	0.00172	0.00688	CcSEcCtD
Tolterodine—Infection—Carmustine—melanoma	0.00171	0.00683	CcSEcCtD
Tolterodine—Dry mouth—Temozolomide—melanoma	0.0017	0.00678	CcSEcCtD
Tolterodine—Pain—Bleomycin—melanoma	0.00168	0.00674	CcSEcCtD
Tolterodine—Tachycardia—Carmustine—melanoma	0.00168	0.00671	CcSEcCtD
Tolterodine—Confusional state—Temozolomide—melanoma	0.00168	0.0067	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00167	0.0067	CcSEcCtD
Tolterodine—Anaphylactic shock—Temozolomide—melanoma	0.00166	0.00665	CcSEcCtD
Tolterodine—Oedema—Temozolomide—melanoma	0.00166	0.00665	CcSEcCtD
Tolterodine—Infection—Temozolomide—melanoma	0.00165	0.0066	CcSEcCtD
Tolterodine—Feeling abnormal—Bleomycin—melanoma	0.00162	0.00649	CcSEcCtD
Tolterodine—Fatigue—Dactinomycin—melanoma	0.00158	0.00634	CcSEcCtD
Tolterodine—Pain—Dactinomycin—melanoma	0.00157	0.00629	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Carmustine—melanoma	0.00157	0.00627	CcSEcCtD
Tolterodine—Oedema peripheral—Docetaxel—melanoma	0.00153	0.00613	CcSEcCtD
Tolterodine—Somnolence—Carmustine—melanoma	0.00153	0.00612	CcSEcCtD
Tolterodine—Feeling abnormal—Dactinomycin—melanoma	0.00151	0.00606	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Temozolomide—melanoma	0.00151	0.00606	CcSEcCtD
Tolterodine—Gastrointestinal pain—Dactinomycin—melanoma	0.0015	0.00601	CcSEcCtD
Tolterodine—Visual impairment—Docetaxel—melanoma	0.0015	0.006	CcSEcCtD
Tolterodine—Somnolence—Temozolomide—melanoma	0.00148	0.00591	CcSEcCtD
Tolterodine—Constipation—Carmustine—melanoma	0.00147	0.00588	CcSEcCtD
Tolterodine—Pain—Carmustine—melanoma	0.00147	0.00588	CcSEcCtD
Tolterodine—Dyspepsia—Temozolomide—melanoma	0.00146	0.00585	CcSEcCtD
Tolterodine—Abdominal pain—Dactinomycin—melanoma	0.00145	0.00581	CcSEcCtD
Tolterodine—Hypersensitivity—Bleomycin—melanoma	0.00145	0.00581	CcSEcCtD
Tolterodine—Flushing—Docetaxel—melanoma	0.00144	0.00578	CcSEcCtD
Tolterodine—Fatigue—Temozolomide—melanoma	0.00143	0.00573	CcSEcCtD
Tolterodine—Pain—Temozolomide—melanoma	0.00142	0.00568	CcSEcCtD
Tolterodine—Constipation—Temozolomide—melanoma	0.00142	0.00568	CcSEcCtD
Tolterodine—Feeling abnormal—Carmustine—melanoma	0.00142	0.00567	CcSEcCtD
Tolterodine—Asthenia—Bleomycin—melanoma	0.00141	0.00565	CcSEcCtD
Tolterodine—Gastrointestinal pain—Carmustine—melanoma	0.00141	0.00563	CcSEcCtD
Tolterodine—Feeling abnormal—Temozolomide—melanoma	0.00137	0.00548	CcSEcCtD
Tolterodine—Abdominal pain—Carmustine—melanoma	0.00136	0.00544	CcSEcCtD
Tolterodine—Gastrointestinal pain—Temozolomide—melanoma	0.00136	0.00544	CcSEcCtD
Tolterodine—Hypersensitivity—Dactinomycin—melanoma	0.00135	0.00542	CcSEcCtD
Tolterodine—Asthenia—Dactinomycin—melanoma	0.00132	0.00527	CcSEcCtD
Tolterodine—Abdominal pain—Temozolomide—melanoma	0.00131	0.00526	CcSEcCtD
Tolterodine—Hypersensitivity—Carmustine—melanoma	0.00127	0.00507	CcSEcCtD
Tolterodine—Diarrhoea—Dactinomycin—melanoma	0.00126	0.00503	CcSEcCtD
Tolterodine—Asthenia—Carmustine—melanoma	0.00123	0.00494	CcSEcCtD
Tolterodine—Hypersensitivity—Temozolomide—melanoma	0.00122	0.0049	CcSEcCtD
Tolterodine—Palpitations—Docetaxel—melanoma	0.0012	0.00479	CcSEcCtD
Tolterodine—Asthenia—Temozolomide—melanoma	0.00119	0.00477	CcSEcCtD
Tolterodine—Diarrhoea—Carmustine—melanoma	0.00118	0.00471	CcSEcCtD
Tolterodine—Chest pain—Docetaxel—melanoma	0.00115	0.00461	CcSEcCtD
Tolterodine—Arthralgia—Docetaxel—melanoma	0.00115	0.00461	CcSEcCtD
Tolterodine—Dizziness—Carmustine—melanoma	0.00114	0.00455	CcSEcCtD
Tolterodine—Diarrhoea—Temozolomide—melanoma	0.00114	0.00455	CcSEcCtD
Tolterodine—Dry mouth—Docetaxel—melanoma	0.00113	0.00451	CcSEcCtD
Tolterodine—Confusional state—Docetaxel—melanoma	0.00111	0.00446	CcSEcCtD
Tolterodine—Oedema—Docetaxel—melanoma	0.00111	0.00442	CcSEcCtD
Tolterodine—Anaphylactic shock—Docetaxel—melanoma	0.00111	0.00442	CcSEcCtD
Tolterodine—Dizziness—Temozolomide—melanoma	0.0011	0.0044	CcSEcCtD
Tolterodine—Infection—Docetaxel—melanoma	0.0011	0.00439	CcSEcCtD
Tolterodine—Tachycardia—Docetaxel—melanoma	0.00108	0.00431	CcSEcCtD
Tolterodine—Headache—Carmustine—melanoma	0.00108	0.00431	CcSEcCtD
Tolterodine—Headache—Temozolomide—melanoma	0.00104	0.00416	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Docetaxel—melanoma	0.00101	0.00403	CcSEcCtD
Tolterodine—Somnolence—Docetaxel—melanoma	0.000982	0.00393	CcSEcCtD
Tolterodine—Dyspepsia—Docetaxel—melanoma	0.000973	0.00389	CcSEcCtD
Tolterodine—Fatigue—Docetaxel—melanoma	0.000953	0.00381	CcSEcCtD
Tolterodine—Constipation—Docetaxel—melanoma	0.000945	0.00378	CcSEcCtD
Tolterodine—Pain—Docetaxel—melanoma	0.000945	0.00378	CcSEcCtD
Tolterodine—Feeling abnormal—Docetaxel—melanoma	0.000911	0.00364	CcSEcCtD
Tolterodine—Gastrointestinal pain—Docetaxel—melanoma	0.000904	0.00362	CcSEcCtD
Tolterodine—Abdominal pain—Docetaxel—melanoma	0.000874	0.00349	CcSEcCtD
Tolterodine—Fesoterodine—ABCB1—melanoma	0.000839	0.415	CrCbGaD
Tolterodine—Hypersensitivity—Docetaxel—melanoma	0.000814	0.00326	CcSEcCtD
Tolterodine—Orphenadrine—SCN10A—melanoma	0.0008	0.395	CrCbGaD
Tolterodine—Asthenia—Docetaxel—melanoma	0.000793	0.00317	CcSEcCtD
Tolterodine—Diarrhoea—Docetaxel—melanoma	0.000756	0.00302	CcSEcCtD
Tolterodine—Dizziness—Docetaxel—melanoma	0.000731	0.00292	CcSEcCtD
Tolterodine—Headache—Docetaxel—melanoma	0.000692	0.00277	CcSEcCtD
Tolterodine—Phenprocoumon—ALB—melanoma	0.000385	0.19	CrCbGaD
Tolterodine—CHRM1—Signaling Pathways—NOTCH1—melanoma	2.82e-05	8.65e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1B—melanoma	2.81e-05	8.64e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOTCH1—melanoma	2.81e-05	8.62e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCND1—melanoma	2.8e-05	8.61e-05	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—AKT1—melanoma	2.78e-05	8.55e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOTCH1—melanoma	2.78e-05	8.54e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CTNNB1—melanoma	2.77e-05	8.52e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CD80—melanoma	2.76e-05	8.48e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CASP3—melanoma	2.76e-05	8.47e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CG—melanoma	2.75e-05	8.46e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APC—melanoma	2.75e-05	8.46e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KIT—melanoma	2.75e-05	8.46e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—NRAS—melanoma	2.75e-05	8.46e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL2—melanoma	2.75e-05	8.46e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CD80—melanoma	2.75e-05	8.45e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KIT—melanoma	2.75e-05	8.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CG—melanoma	2.75e-05	8.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APC—melanoma	2.75e-05	8.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—NRAS—melanoma	2.75e-05	8.43e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL6—melanoma	2.74e-05	8.41e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PRKCA—melanoma	2.73e-05	8.37e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CD80—melanoma	2.72e-05	8.37e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ABCB1—melanoma	2.72e-05	8.37e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGF—melanoma	2.72e-05	8.36e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MMP9—melanoma	2.72e-05	8.36e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KIT—melanoma	2.72e-05	8.35e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CG—melanoma	2.72e-05	8.35e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APC—melanoma	2.72e-05	8.35e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—NRAS—melanoma	2.72e-05	8.35e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGF—melanoma	2.71e-05	8.34e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CDKN1A—melanoma	2.71e-05	8.33e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PTEN—melanoma	2.7e-05	8.31e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ERCC2—melanoma	2.7e-05	8.3e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ABCB1—melanoma	2.7e-05	8.29e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NFKB1—melanoma	2.69e-05	8.27e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGF—melanoma	2.69e-05	8.26e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCND1—melanoma	2.68e-05	8.24e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CTNNB1—melanoma	2.66e-05	8.16e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—AKT1—melanoma	2.64e-05	8.11e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—MAPK3—melanoma	2.64e-05	8.1e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—MAPK3—melanoma	2.63e-05	8.08e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—melanoma	2.61e-05	8e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—MAPK3—melanoma	2.6e-05	8e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1A—melanoma	2.6e-05	7.97e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTEN—melanoma	2.59e-05	7.96e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—BRAF—melanoma	2.59e-05	7.95e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—BRAF—melanoma	2.58e-05	7.93e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NFKB1—melanoma	2.58e-05	7.92e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP17A1—melanoma	2.57e-05	7.89e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—BRAF—melanoma	2.56e-05	7.85e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—AKT1—melanoma	2.53e-05	7.76e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1—melanoma	2.52e-05	7.75e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CB—melanoma	2.52e-05	7.73e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1—melanoma	2.51e-05	7.72e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—MAPK1—melanoma	2.51e-05	7.71e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—melanoma	2.51e-05	7.71e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PRKCA—melanoma	2.51e-05	7.7e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—MAPK1—melanoma	2.5e-05	7.69e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—melanoma	2.5e-05	7.68e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—melanoma	2.49e-05	7.66e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1—melanoma	2.49e-05	7.65e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ERCC2—melanoma	2.49e-05	7.64e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PRKCA—melanoma	2.48e-05	7.63e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—MAPK1—melanoma	2.48e-05	7.61e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—melanoma	2.48e-05	7.61e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ERCC2—melanoma	2.46e-05	7.57e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—melanoma	2.44e-05	7.5e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAP2K1—melanoma	2.44e-05	7.49e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAP2K1—melanoma	2.43e-05	7.46e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GNA11—melanoma	2.43e-05	7.45e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CD—melanoma	2.42e-05	7.44e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—STAT3—melanoma	2.42e-05	7.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CD—melanoma	2.41e-05	7.41e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NRAS—melanoma	2.41e-05	7.41e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAP2K1—melanoma	2.41e-05	7.39e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	2.4e-05	7.37e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PIK3CA—melanoma	2.39e-05	7.34e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CD—melanoma	2.39e-05	7.34e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—FASN—melanoma	2.37e-05	7.29e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—KRAS—melanoma	2.37e-05	7.28e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—PIK3CA—melanoma	2.37e-05	7.27e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—KRAS—melanoma	2.36e-05	7.26e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—KRAS—melanoma	2.34e-05	7.19e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—melanoma	2.34e-05	7.19e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC5A5—melanoma	2.34e-05	7.17e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—FGF2—melanoma	2.32e-05	7.12e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—STAT3—melanoma	2.32e-05	7.12e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK3—melanoma	2.31e-05	7.1e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—FGF2—melanoma	2.31e-05	7.1e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NRAS—melanoma	2.31e-05	7.1e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—FGF2—melanoma	2.29e-05	7.03e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GNAQ—melanoma	2.26e-05	6.93e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CD44—melanoma	2.26e-05	6.93e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—melanoma	2.25e-05	6.9e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.24e-05	6.88e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK3—melanoma	2.21e-05	6.8e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK1—melanoma	2.2e-05	6.75e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—melanoma	2.2e-05	6.75e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CA—melanoma	2.18e-05	6.69e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTEN—melanoma	2.17e-05	6.68e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CA—melanoma	2.17e-05	6.67e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MDM2—melanoma	2.17e-05	6.66e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1B1—melanoma	2.16e-05	6.64e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MDM2—melanoma	2.16e-05	6.64e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—melanoma	2.15e-05	6.61e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CA—melanoma	2.15e-05	6.6e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MDM2—melanoma	2.14e-05	6.58e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ERBB2—melanoma	2.14e-05	6.57e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CG—melanoma	2.13e-05	6.56e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ERBB2—melanoma	2.13e-05	6.55e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ERBB2—melanoma	2.11e-05	6.48e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CB—melanoma	2.11e-05	6.48e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK1—melanoma	2.11e-05	6.47e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—melanoma	2.11e-05	6.47e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CB—melanoma	2.1e-05	6.46e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CB—melanoma	2.08e-05	6.4e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KRAS—melanoma	2.08e-05	6.38e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARG—melanoma	2.06e-05	6.33e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.04e-05	6.27e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—melanoma	2.03e-05	6.23e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—melanoma	2.02e-05	6.21e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HRAS—melanoma	2.01e-05	6.19e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HRAS—melanoma	2.01e-05	6.17e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—melanoma	2e-05	6.15e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HRAS—melanoma	1.99e-05	6.11e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KRAS—melanoma	1.99e-05	6.11e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1B—melanoma	1.98e-05	6.08e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1B—melanoma	1.97e-05	6.06e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CG—melanoma	1.96e-05	6.03e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—AKT1—melanoma	1.96e-05	6.02e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1B—melanoma	1.96e-05	6.01e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—AKT1—melanoma	1.95e-05	6e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CG—melanoma	1.95e-05	5.98e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CASP3—melanoma	1.94e-05	5.96e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL2—melanoma	1.94e-05	5.95e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CASP3—melanoma	1.93e-05	5.94e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—AKT1—melanoma	1.93e-05	5.94e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL2—melanoma	1.93e-05	5.93e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—melanoma	1.93e-05	5.92e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—melanoma	1.92e-05	5.91e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CASP3—melanoma	1.92e-05	5.89e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL2—melanoma	1.91e-05	5.88e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CA—melanoma	1.91e-05	5.86e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—melanoma	1.9e-05	5.85e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARG—melanoma	1.89e-05	5.82e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—melanoma	1.89e-05	5.8e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—melanoma	1.88e-05	5.79e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARG—melanoma	1.88e-05	5.77e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CD—melanoma	1.88e-05	5.76e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CTNNB1—melanoma	1.87e-05	5.75e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—melanoma	1.87e-05	5.73e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CTNNB1—melanoma	1.87e-05	5.73e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALB—melanoma	1.85e-05	5.69e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CTNNB1—melanoma	1.85e-05	5.67e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—melanoma	1.85e-05	5.67e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—melanoma	1.83e-05	5.63e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—melanoma	1.83e-05	5.62e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1A—melanoma	1.83e-05	5.61e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CA—melanoma	1.83e-05	5.61e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTEN—melanoma	1.82e-05	5.6e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1A—melanoma	1.82e-05	5.6e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTEN—melanoma	1.82e-05	5.58e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NFKB1—melanoma	1.81e-05	5.58e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—melanoma	1.81e-05	5.56e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NFKB1—melanoma	1.81e-05	5.56e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1A—melanoma	1.8e-05	5.54e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTEN—melanoma	1.8e-05	5.53e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NFKB1—melanoma	1.79e-05	5.5e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ABCB1—melanoma	1.78e-05	5.47e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—AKT1—melanoma	1.78e-05	5.47e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—AKT1—melanoma	1.77e-05	5.45e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—melanoma	1.77e-05	5.43e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HRAS—melanoma	1.77e-05	5.42e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—AKT1—melanoma	1.76e-05	5.39e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CD—melanoma	1.73e-05	5.3e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CD—melanoma	1.71e-05	5.26e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALB—melanoma	1.7e-05	5.23e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HRAS—melanoma	1.69e-05	5.19e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—melanoma	1.69e-05	5.19e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALB—melanoma	1.69e-05	5.19e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—melanoma	1.65e-05	5.06e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—melanoma	1.64e-05	5.04e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PRKCA—melanoma	1.64e-05	5.03e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CB—melanoma	1.64e-05	5.02e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—STAT3—melanoma	1.63e-05	5.01e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NRAS—melanoma	1.63e-05	5e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—melanoma	1.63e-05	4.99e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—STAT3—melanoma	1.63e-05	4.99e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ERCC2—melanoma	1.63e-05	4.99e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NRAS—melanoma	1.62e-05	4.98e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—melanoma	1.62e-05	4.98e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—melanoma	1.62e-05	4.97e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—STAT3—melanoma	1.61e-05	4.95e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NRAS—melanoma	1.61e-05	4.93e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—AKT1—melanoma	1.56e-05	4.79e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK3—melanoma	1.56e-05	4.79e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK3—melanoma	1.55e-05	4.77e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK3—melanoma	1.54e-05	4.73e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CA—melanoma	1.53e-05	4.71e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—melanoma	1.52e-05	4.66e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—melanoma	1.51e-05	4.64e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CB—melanoma	1.5e-05	4.62e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—melanoma	1.5e-05	4.6e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—AKT1—melanoma	1.49e-05	4.59e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CB—melanoma	1.49e-05	4.58e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—melanoma	1.49e-05	4.58e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK1—melanoma	1.48e-05	4.55e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—melanoma	1.48e-05	4.55e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK1—melanoma	1.48e-05	4.54e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—melanoma	1.48e-05	4.54e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—melanoma	1.48e-05	4.54e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK1—melanoma	1.46e-05	4.5e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—melanoma	1.46e-05	4.5e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTEN—melanoma	1.41e-05	4.34e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KRAS—melanoma	1.4e-05	4.3e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KRAS—melanoma	1.4e-05	4.29e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KRAS—melanoma	1.38e-05	4.25e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTEN—melanoma	1.3e-05	3.99e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTEN—melanoma	1.29e-05	3.96e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CA—melanoma	1.29e-05	3.95e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CG—melanoma	1.28e-05	3.94e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CA—melanoma	1.28e-05	3.94e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CA—melanoma	1.27e-05	3.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AKT1—melanoma	1.25e-05	3.85e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—melanoma	1.24e-05	3.82e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—melanoma	1.24e-05	3.81e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARG—melanoma	1.24e-05	3.81e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—melanoma	1.23e-05	3.77e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HRAS—melanoma	1.19e-05	3.66e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HRAS—melanoma	1.19e-05	3.64e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HRAS—melanoma	1.17e-05	3.61e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—melanoma	1.14e-05	3.5e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—melanoma	1.14e-05	3.49e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CD—melanoma	1.13e-05	3.47e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—melanoma	1.12e-05	3.45e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALB—melanoma	1.11e-05	3.42e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT1—melanoma	1.05e-05	3.23e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT1—melanoma	1.05e-05	3.22e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT1—melanoma	1.04e-05	3.19e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CA—melanoma	9.97e-06	3.06e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CB—melanoma	9.84e-06	3.02e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—melanoma	9.75e-06	2.99e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CA—melanoma	9.17e-06	2.82e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CA—melanoma	9.09e-06	2.79e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTEN—melanoma	8.5e-06	2.61e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AKT1—melanoma	8.14e-06	2.5e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AKT1—melanoma	7.49e-06	2.3e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AKT1—melanoma	7.43e-06	2.28e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CA—melanoma	6e-06	1.84e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKT1—melanoma	4.9e-06	1.5e-05	CbGpPWpGaD
